1. Home
  2. INHD vs PHGE Comparison

INHD vs PHGE Comparison

Compare INHD & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inno Holdings Inc.

INHD

Inno Holdings Inc.

HOLD

Current Price

$1.01

Market Cap

9.6M

Sector

N/A

ML Signal

HOLD

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$4.68

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INHD
PHGE
Founded
2019
2015
Country
Hong Kong
United States
Employees
N/A
57
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.6M
9.2M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
INHD
PHGE
Price
$1.01
$4.68
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
90.7K
65.7K
Earning Date
05-01-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
17.61
N/A
EPS
N/A
N/A
Revenue
$2,846,250.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
221.43
N/A
52 Week Low
$0.06
$0.25
52 Week High
$15.90
$8.50

Technical Indicators

Market Signals
Indicator
INHD
PHGE
Relative Strength Index (RSI) 39.85 42.86
Support Level $0.98 $4.00
Resistance Level $1.18 $5.99
Average True Range (ATR) 0.05 0.76
MACD -0.01 -0.18
Stochastic Oscillator 2.56 4.50

Price Performance

Historical Comparison
INHD
PHGE

About INHD Inno Holdings Inc.

Inno Holdings Inc is a building technology company with a mission to transform the construction industry with its proprietary cold-formed steel-framing technology and other innovations. It is a manufacturer of cold-formed-steel members and prefabricated homes. It offers a full range of services required to transform raw materials into precise steel framing products and prefabricated homes. The company sells these finished products either to businesses or directly to customers. The finished products and cold-formed-steel members are used in a variety of building types, including residential, commercial, industrial and infrastructure.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: